SIRIO launches GummiBiotic range at CPHI Milan

The new market-ready range includes clinically-researched strains for immune health, IBS symptoms and fat burning.

SIRIO Pharma (SIRIO^®) – the global nutraceutical contract development and manufacturing organisation (CDMO) – will launch its new GummiBiotics^™ at CPHI Milan for leading nutraceutical and healthcare brands. These innovative gummies are powered by branded, science-backed macrobiotic strains and are designed to support various health benefits. The range includes three vegetarian gummies, each uniquely formulated for specific needs: GummiBiotics Defense to help support immune health, GummiBiotics IBS Ease to alleviate IBS symptoms, and GummiBiotics Lean to aid in abdominal fat burning.

GummiBiotics by SIRIO are launching at the world’s largest pharma event as demand for natural alternative treatments for common health conditions continues to grow. The biotic supplement segment already accounts for a quarter of all supplements sold, surpassing $3bn in sales in 2023, ¹with the gummy category growing at an average of 14% CAGR since 2020². Consumers are increasingly prioritising natural health solutions, while also looking for products that combine proven efficacy with enjoyable dose forms.

The GummiBiotics Defense is powered by 500mg of EpiCor^® postbiotic per serving – a unique ingredient that has been the focus of numerous clinical trials for immune and gut health – with added Zinc (5mg) to support the normal function of the immune system. It is a first-to-market postbiotic and expected to see rapid sales growth as the only gummy available featuring EpiCor^®.

Irritable Bowel Syndrome (IBS) is a common digestive disorder affecting 15% of people worldwide³, causing symptoms like abdominal pain, bloating, diarrhoea, or constipation, and many consumers are looking for natural products to help manage symptoms. In another first, Sirio has formulated its GummiBiotics IBS Ease with ADM’s proprietary ES1 Postbiotic – which, in clinical studies, is shown to help moderate some symptoms of IBS-D⁴ and deliver a reduction in occasional diarrhoea*. The gummy is further enhanced with xylo-oligosaccharides – with a study showing that xylo-oligosaccharides may help comfort diarrhoea-dominant Irritable Bowel Syndrome (IBS-D)⁵ – and Calcium which is known to contribute to the normal functioning of digestive enzymes⁶.

The third new product to launch is the GummiBiotics Lean which features a specially formulated combination of apple cider vinegar, Vitamin B6 and DE111^® probiotic [containing 5bn CFU] – a strain of Bacillus subtilis that is clinically proven to significantly reduce body fat percentage. The gummy’s metabolic action is further enhanced by 500mg of Sirio’s own premium Apple Cider Vinegar Natuful^™ Postbiotic. The formulation is market-ready, powered by science-backed microbiomes, and supports healthy body composition.

Sara Lesina, General Manager Sirio Europe & Americas, commented:

“At SIRIO we are very proud of our R&D capabilities, where we continue to invest a significant portion of our earnings: our technical and formulation teams account for 13% of our total employee base, something unique for a CDMO. We are constantly working with our customers and our experts to not just follow the trends but make first-in-class new products that will drive sales in new areas – and each one of these concepts is a true first for nutraceutical brands. So we are incredibly excited to launch the new GummiBiotics range as it continues building on our partnerships with some of the best ingredient suppliers and it combines the benefits of science-backed biotics with gummies that are truly delicious: this range will completely change the experience for consumers.”

*The study showed statistically significant results in improvements in IBS-SSS scores and quality of life scores (based on the IBS-QoL) compared to placebo, along with an improvement of frequency of watery stools compared to placebo, a significant reduction of mean APS-NRS score (related to abdominal discomfort) and a significant reduction in stress versus placebo, as measured by the State-Trait Anxiety Index (STAI).

• ¹ Informa NBJ: Supplement Business Report, 2024
• ² QY Research: Global Functional Gummies Market Research Report
• ³ World Gastroenterology Organisation (WGO), 2023
• ⁴ Participants who consumed ES1 Postbiotic (Heat-treated Bifidobacterium longum CECT 7347) reduced their IBS-SSS score from moderate to mild in 12 weeks
• ⁵ Srivastava S, Basak U, Naghibi M, et al. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome[J]. Gut Microbes, 2024, 16(1): 2338322.
• ⁶ EFSA Claim